Hikma Pharmaceuticals (LON:HIK) Stock Gets Price Target Reduction from Berenberg Bank

Key Points

• Berenberg Bank lowered its price target on Hikma Pharmaceuticals from GBX 2,100 to GBX 2,050, while maintaining a Buy rating; the revised target implies 23.05% upside from the current share price.
• Analyst sentiment remains positive: MarketBeat reports a consensus Buy rating and an average price target of GBX 1,986.25. Deutsche Bank also cut its target, while Citigroup raised its target; both retained Buy ratings.
• Hikma raised its growth outlook for branded medicines but lowered its outlook for Injectables, leaving mixed business signals for investors.

Hikma Pharmaceuticals (LON:HIK - Get Free Report) had its target price lowered by equities research analysts at Berenberg Bank from GBX 2,100 to GBX 2,050 in a research note issued on Monday, Digital Look reports. The brokerage presently has a "buy" rating on the stock. Berenberg Bank's price target would suggest a potential upside of 23.05% from the stock's current price.

Several other research analysts also recently commented on HIK. Deutsche Bank Aktiengesellschaft reduced their price objective on Hikma Pharmaceuticals from GBX 2,050 to GBX 2,000 and set a "buy" rating on the stock in a report on Friday. Citigroup upped their target price on Hikma Pharmaceuticals from GBX 1,700 to GBX 1,870 and gave the stock a "buy" rating in a report on Wednesday, August 12th. Finally, Jefferies Financial Group reiterated a "buy" rating and issued a GBX 2,025 target price on shares of Hikma Pharmaceuticals in a report on Thursday. Four research analysts have rated the stock with a Buy rating. According to data from MarketBeat.com, the company has a consensus rating of "Buy" and an average target price of GBX 1,986.25.

Hikma Pharmaceuticals Stock Performance

Hikma Pharmaceuticals stock opened at GBX 1,666 on Monday. The company has a 50 day moving average price of GBX 1,627.89 and a 200-day moving average price of GBX 1,508.93. The company has a debt-to-equity ratio of 77.57, a quick ratio of 1.27 and a current ratio of 1.98. Hikma Pharmaceuticals has a fifty-two week low of GBX 1,187 and a fifty-two week high of GBX 1,762. The company has a market capitalization of £3.45 billion, a PE ratio of 9.47, a P/E/G ratio of 2.38 and a beta of 0.65.

More Hikma Pharmaceuticals News

Here are the key news stories impacting Hikma Pharmaceuticals this week:

• Positive Sentiment: Hikma raised its growth outlook for branded medicines, a positive offset to weakness elsewhere in the business. Hikma Raises Branded Growth Outlook, Narrows 2026 Profit Guidance
• Neutral Sentiment: The company maintained its 2026 revenue guidance and narrowed its operating profit forecast to $740–$760 million. The tighter range gives investors more clarity, but the outlook remains a key focus. Hikma Pharmaceuticals Maintains 2026 Revenue Guidance and Narrows Operating Profit Forecast
• Neutral Sentiment: Jefferies reaffirmed its Buy rating with a GBX 2,025 target, while Deutsche Bank cut its target from GBX 2,050 to GBX 2,000 but retained a Buy rating. Deutsche Bank rating information
• Negative Sentiment: Hikma lowered its outlook for Injectables. That business outlook revision is the clearest near-term headwind and likely weighs on sentiment despite the brighter branded-medicines forecast. Hikma Pharmaceuticals shares down as cuts Injectables outlook

About Hikma Pharmaceuticals

At Hikma we help put better health within reach, every day. By creating high-quality medicines and making them accessible to the people who need them, we help to shape a healthier world that enriches all our communities. We help deliver this by living our culture, delivering our strategy, and acting responsibly. We are a trusted, reliable partner and dependable source of over 820+ (as of Feb 2026) high-quality generic, specialty and branded pharmaceutical products that hospitals, physicians and pharmacists need to treat their patients across North America, MENA and Europe.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.